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investigating how the OVH model should be modified to be 
suitable as a plan QA tool for prostate patients. 
 
Symposium: Targeting DNA repair / DDR pre-clinical 
evidence  
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The human ataxia telangiectasia and Rad3-related protein 
(ATR) kinase is activated by DNA damage and replication 
stress as a central transducer of a checkpoint signaling 
pathway. Subsequent to activation, ATR phosphorylates many 
substrates, including the kinase Chk1, which regulates cell-
cycle progression, replication fork stability, and DNA repair. 
All of the three mentioned events promote cell survival 
during replication stress and in cells with DNA damage. It was 
hypothesiszed that ATR inhibitors would be therapeutically 
useful, with a predicted specificity for tumors sparing normal 
cells. Since the introduction of potent ATR inhibitors a hand 
full of studies in conjuction with radiotherapy has been 
published including our own work where we showed 
sensitization of pancreatic cancer in vitro and in vivo to 
radiotherapy in conjunction with VE-822 (=VX-970), an ATR 
inhibitor. The drug decreased maintenance of cell-cycle 
checkpoints, increased persistent DNA damage and decreased 
homologous recombination in irradiated cancer cells. 
Furthermore, we observed decreased survival of pancreatic 
cancer cells but not normal cells in response to XRT or 
gemcitabine. VE-822 markedly prolonged growth delay of 
pancreatic cancer xenografts after XRT and gemcitabine-
based chemoradiation without augmenting normal cell or 
tissue toxicity. Others have shown that different tumours 
such as head and neck squamous cell carcinoma or 
promyelocytic leukaemia were also sensitized to radiation by 
co-treatment with an ATR inhibitor. Aditionally, human 
tumor cells were also sensitized to high LET radiation. The 
first clinical early phase trials combining ATR inhibitors with 
radiotherapy or chemotherapy are underway to generate 
important insights into the effects of ATR inhibition in 
humans and the potential role of inhibiting this kinase in the 
treatment of human malignancies. 
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ATR and ATM are protein kinases activated at stalled and 
collapsed replication forks and DNA double-strand breaks 
(DSBs), respectively, where they function to maintain 
genome integrity by mediating cell cycle checkpoints and 
DNA repair. ATM has been widely studied since ataxia 
telangiectasia individuals who express no ATM protein are the 
most radiosensitive humans identified. It has therefore been 
postulated that ATM kinase inhibitors (ATMi’s) will increase 
the efficacy of radiotherapy. ATR has also been widely 
studied, but advances have been complicated by the finding 
that ATR is an essential protein in mice and mammalian cells. 
Nevertheless, pharmacologic ATR and ATM kinase inhibitors 
have been identified and these sensitize cancer cells to 
ionizing radiation (IR) in tissue culture. ATR kinase inhibitors 
(ATRi’s) also synergize with cisplatin to induce cell death in 
tissue culture. Since concurrent cisplatin and radiation is 
used as standard of care for locally advanced and metastatic 
NSCLC patients, ATR kinase inhibition may significantly 
improve the efficacy of first line treatment in tens of 
thousands of patients in the USA every year. Until recently, 
however, in vivo studies have been limited by the absence of 
bioavailable ATR and ATM kinase inhibitors.  
Here we describe orally active and bioavailable ATR and ATM 
kinase inhibitors and show that, in contrast to expectations, 
ATRi is surprisingly well tolerated. We show that cisplatin-
ATRi induces a complete response in ATM-deficient lung 
cancer xenografts and potentiates the effect of cisplatin in 
p16INK4A-deficient lung cancer xenografts. We also show that 
conformal radiation-ATRi and radiation-ATMi induce profound 
responses in an autochthonous KrasG12D/Twist1 mouse model 
of lung adenocarcinoma, and that the efficacy of radiation-
ATRi for the treatment of lung cancer appears to be better 
than that of radiation-ATMi due to lower toxicity. 
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An underlying hallmark of cancers is their genomic instability, 
which is associated with a greater propensity to accumulate 
DNA damage. Historical treatment of cancer by radiotherapy 
and DNA-damaging chemotherapy is based on this principle, 
yet it is accompanied the significant risk of collateral damage 
to normal tissue and unwanted side effects. Targeted therapy 
based on inhibiting the DNA damage response (DDR) in 
cancers, either alone or in combination, offers the potential 
for a greater therapeutic window by tailoring treatment to 
patients with tumours lacking specific DDR functions. The 
recent approval of olaparib (Lynparza), the poly (ADP-ribose) 
polymerase (PARP) inhibitor for treating tumours harbouring 
BRCA1 or BRCA2 mutations, represents the first medicine 
based on this principle, exploiting an underlying cause of 
tumour formation that also represents an Achilles’ heel. 
Different forms of DNA damage evoke responses by different 
repair mechanisms and signalling pathways and the choice of 
pathway will also be influenced by the phase of the cell cycle 
in which the damage occurs. DDR represents a good source of 
anticancer drug targets as there are at least three key 
aspects of DDR that are different in cancers compared with 
normal cells. These are a) the loss of one or more DDR 
capability b) the increased levels of replication stress and c) 
the higher levels of endogenous DNA damage in cancer cells 
compared to normal cells.  
This talk will focus on examples of how each of these 
concepts is currently being exploited to treat cancer. As an 
example of the exploitation of the first concept, the use of 
PARP inhibitors to treat cancers deficient in BRCA1 and 
BRCA2 gene function, as well as other homologous 
recombination repair deficiencies, will be presented. The 
second concept - the exploitation of high levels of replication 
stress in cancers, will be exemplified through data presented 
resulting from the use of inhibitors of ATR and WEE1. As part 
of the discussion on how best to exploit the higher levels of 
endogenous DNA damage in cancers, the focus will be on the 
challenges associated with expanding the therapeutic window 
for the use of DDR inhibitors in combination with DNA 
damaging agents such as radiation and chemotherapy. 
Finally, the ambition of how best to realise the full potential 
of DNA damage response-based therapy will be discussed 
including the use of different synergistic combinations in a 
personalized healthcare approach. 
 
 
Figure highlighting the differences in cancer DNA damage 
response compared to normal cells that provides the 
